Written by
Mark Lazell
Share article:
It’s been around three weeks since ambient AI medical documentation and data solutions vendor Augmedix published its Q1 2024 financial results. In that time, around 60% has been wiped off its share value, an investor response that followed the release of its Q1 2024 revenues of $13.47M, which were 40% up on Q1 2023.
The Signify View
Investors were evidently spooked by the company’s decision to moderate its revenue forecast for 2024, based on its current outlook, to $52M-$55 million (circa $60M previously). This comes against a…
Read the full insight with a Signify Premium Insights - Digital Health subscription
